![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults
 
|
|
|
Reported by Jules Levin
IDWeek2017/IDSA, October 4-8, 2017, San Diego  
Chloe Orkin1, Joseph Eron2, Jean-Michel Molina3, Eugenia Negredo4, Joseph Gathe5,
Erika Van Landuyt6, Erkki Lathouwers6, Veerle Hufkens6, Romana Petrovic6, Magda Opsomer6,
on behalf of the EMERALD study group  
1Barts Health NHS Trust, London, UK; 2The University of North Carolina School of Medicine, Chapel Hill, NC; 3Department of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France; 4Germans Trias i Pujol University Hospital, Badalona, Spain; 5Therapeutic Concepts, Houston, Texas, USA; 6Janssen Pharmaceutica NV, Beerse, Belgium
![IAS1](../images/100917/100917-3/IAS1.gif)
![IAS2](../images/100917/100917-3/IAS2.gif)
![IAS3](../images/100917/100917-3/IAS3.gif)
![IAS4](../images/100917/100917-3/IAS4.gif)
![IAS5](../images/100917/100917-3/IAS5.gif)
![IAS6](../images/100917/100917-3/IAS6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|